77-52-1 ursolic acid free sample supplier factory CAS NO.77-52-1

Ursolic acid displayed lower toxicity than OA, 0.95 up from 0.10 mg/mL, respectively, but the data ranged depending on the raw material source, the extraction solvent, the type of activity, the disease, the clinical, cosmetically or pharmacological study, the study in animal or human, etc. Bioavailability studies confirmed a low plasma concentrations of UA in plasma of mice orally administered with high dose of UA, suggested either high binding activity in organs or low bioavailability or metabolism by the gut wall of the intestine and liver.

Despite many aspects of the biological activities of UA are not completely understood, the pharmacological effects could be attributed, in part, to their action against free radicals. Cardiovascular protection and anti-hyperlipidemic effect Cardiovascular protection, antihyperlipidemic (triglycerides, total cholesterol and lipoprotein fractions), antioxidant (glutathione peroxidase and superoxide dismutase activities), hypoglycemic effects and prevention of hypertension were observed in rats, displaying UA a low toxicity (LC50 0.95 mg/mL). Ursolic acid fed to rabbits and rats prevented the experimental atherosclerosis and lowered blood cholesterol. A strong synergistic effect derived from the combination of ursolic acid and artesunate can reduce both triglyceride and cholesterol, showing more potent effects than either agent alone. Ethanolic extract from the stems and roots of Celastrus orbiculatus Thunb decreases athero-susceptibility in lipoproteins and the aorta of guinea pigs fed a high-fat diet, and increases high-density lipoprotein; likewise, it reduce lipid accumulation and promote reverse cholesterol transport in vivo and in vitro.

A cell-permeable plant-derived pentacyclic triterpene acid that displays anti-inflammatory, immunomodulatory, and antitumor activities. Shown to inhibit the phosphatase activity of SHP2, PTP1B, and TCPTP (IC₅₀ = 2.73, 3.08 and 3.33 µM, respectively) as well as induce IR autophosphorylation independent of its phosphatase inhibitory activity. Ursolic acid is also reported to inhibit NF-κB and STAT3 pathway activation in cancer cultures, resulting in enhanced sensitivity to chemotherapy agents and apoptotic cell death.